Innovative Entities Converge on 'China Heart Valley' to Build a Cardiovascular Medical Device and Pharmaceutical Innovation Cluster

(Source:BAHEAL PHARMACEUTICAL GROUP(Group)

Source: BAHEAL PHARMACEUTICAL GROUP

On September 27, 2025, the "2025 China Heart Congress Innovation and Transformation Forum and Jingxi Innovative Pharmaceutical and Device Industry Development Conference" was held in Beijing. This conference was jointly organized by the National Cardiovascular Center, relevant Beijing municipal departments, and the Mentougou District Government, fully integrating the elements of "government, industry, academia, research, finance, application, and service" to drive momentum for the construction of "China Heart Valley" and the high-quality development of Beijing's pharmaceuticals and healthcare industry.

Conference Venue

During the conference,National Key Laboratory of Cardiovascular Diseases (referred to as "NKLCVD"), BrioHealth Solutions (referred to as "BrioHealth"), and Beijing Fuwai Heart Valley Technology Co., Ltd. officially announced their move into "China Heart Valley.", and held an inauguration ceremony. This not only marks the further gathering and improvement of industrial elements in "China Heart Valley," but also injects crucial momentum into breakthrough innovations in cardiovascular pharmaceuticals and medical devices.

Opening Ceremony

Among the innovative entities that have settled in this time,The National Key Laboratory of Cardiovascular Diseases was jointly established by Fuwai Hospital of the Chinese Academy of Medical Sciences, Shenzhen Hospital of Fuwai Hospital of the Chinese Academy of Medical Sciences, and BAHEAL PHARMACEUTICAL GROUP.BAHEAL PHARMACEUTICAL GROUP, relying on its industrial resources and innovative incubation capabilities, has built a cluster of industries focused on the transformation of scientific research achievements in the cardiovascular field around the Full Weight Laboratory. This industrial cluster, as the core structure of "China Heart Valley," is continuously attracting more innovative forces to gather, collaboratively creating an internationally leading source of innovation in cardiovascular pharmaceuticals and devices.

BrioHealth Solutions, as an innovative enterprise incubated by BAHEAL PHARMACEUTICAL GROUP,Developed China's first fully magnetically suspended artificial heart approved for marketing with complete independent intellectual property rightsThe key performance indicators of its products, such as blood compatibility, implant invasiveness, and reliability, have reached internationally leading levels. Currently, the product has been implanted in hundreds of cases in China, saving the lives of many patients with severe heart failure. It has also initiated clinical trials in the United States, becoming the first original active implantable medical device from China to receive FDA approval for clinical trials in the U.S. The first phase of safety trials has been completed in the United States, and large-scale confirmatory studies are now underway.This time, BrioHealth Solutions, driven by BAHEAL PHARMACEUTICAL GROUP, has officially settled in "China Heart Valley".，will further improve the layout of the cardiovascular innovation pharmaceuticals and devices industrial cluster, and will also leverage the scientific research resources of the National Key Laboratory and the industrial cluster incubation system to accelerate the R&D and industrialization of new products.

Currently,"China Heart Valley" has successfully incubated three cardiovascular innovative drug and device research and transformation platform enterprises.As innovative entities with distinct characteristics continue to join, the innovation ecosystem will also be continuously improved, accelerating the transition into a new phase of high-quality development. BAHEAL PHARMACEUTICAL GROUP will continue to uphold the responsibility and original aspiration of being an "industrial investor," focusing on major national strategies and actual clinical needs. The group will keep delving deeply into significant disease areas such as cardiovascular diseases, incubating truly clinically valuable and internationally competitive innovative pharmaceuticals and medical devices to genuinely benefit patients worldwide.